GoKawiilAlgonquin trial tests BPd combination in relapsed multiple myeloma across nine Canadian sites
Researchers report interim results from the ongoing Algonquin study, a multicentre, open-label trial evaluating a BPd drug combination in patients with relapsed or refractory multiple myeloma. The analysis covers patients enrolled in the trial's second phase, with data collected through late October 2025 after enrollment closed in September 2022. Eligible patients had failed prior treatments including lenalidomide and proteasome inhibitors, but had not previously received pomalidomide or BCMA-targeted therapy.